EFFECTIVENESS OF TICAGRELOR COMPARED TO CLOPIDOGREL IN REDUCING THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY HEART DISEASE AFTER PERCUTANEOUS CORONARY INTERVENTION
Journal Title: International Journal of Pharmacy and Pharmaceutical Sciences - Year 2017, Vol 9, Issue 9
Abstract
Objective: Antiplatelet therapy is recommended in patients with coronary heart disease (CHD) who had the percutaneous coronary intervention (PCI) procedure to reduce major adverse cardiovascular events (MACE). There has been a lack of population-based studies that showed the superior effectiveness of ticagrelor over clopidogrel and similar studies have not been conducted in Indonesia yet. The aim of the study was to investigate the effectiveness of ticagrelor compared to clopidogrel in reducing the risk of MACE in patients with CHD after PCI.Methods: A retrospective cohort study with 1-year follow-up was conducted. 361 patients consisted of 111 patients with ticagrelor exposure and 250 patients with clopidogrel exposure. The primary outcome was MACE, defined as a composite of repeat revascularization, myocardial infarction, or all-cause death. The association between antiplatelet exposure and the MACE was analyzed with Cox proportional hazard regression, adjusted for sex, age, comorbid, PCI procedures and concomitant therapy.Results: MACE occurred in 22.7% of the subjects. Clopidogrel had a significantly higher risk of MACE compared with ticagrelor (28.8%, vs 9.0%, hazard ratio (HR): 1.96 (95% CI 1.01 to 3.81, p=0.047). There were no significant differences in risk of repeat revascularization (20.40% vs 5.40%, HR: 2.32, 95% CI 0.99 to 5.42, p = 0.05), myocardial infarction (11.60% vs 3.60%, HR: 2.08, 95% CI, 0.73 to 5.93, p = 0.17), and death (1.60% vs 1.80%, HR: 0.77, 95% CI, 0.14 to 4.25, p = 0.77).Conclusion: Clopidogrel had a higher risk of MACE compared to clopidogrel in patients with CHD after PCI, but there were no significant differences in the risk of repeat revascularization, myocardial infarction, and all-cause death.Â
Authors and Affiliations
Hendra Wana Nur’amin, Iwan Dwiprahasto, Erna Kristin
Keywords
Related Articles
- EP ID EP575513
- DOI 10.22159/ijpps.2017v9i9.20361
- Views 115
- Downloads 0
HYPOGLYCEMIC AND HYPOLIPIDEMIC EFFECTS OF ANNONA MURICATA L. LEAF ETHANOL EXTRACT
Objective: The aim of this study was to investigate hypoglycemic and hypolipidemic effects of Annona muricata leaf ethanol extract. This study also investigated phytochemical analysis of the extract and improvement in th...
LIBIDIBIA FERREA (MART. EX TUL) L. P. QUEIROZ VAR. FERREA: PHARMACOLOGICAL, PHYTOCHEMICAL AND BOTANICAL ASPECTS
Libidibia ferrea, popularly known as “pau ferro†or “jucáâ€, is an important medicinal plant employed for the treatment of various ailments in the North and Northeast regions of Brazil, including anemia, inflamma...
A STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF SIMVASTATIN AND NIACIN IN A COMBINED DOSAGE FORM
Objective: To develop a simple, selective and rapid stability-indicating reverse phase high performance liquid chromatography (RP-HPLC) method and validate as per ICH guidelines for simultaneous determination of simvasta...
SYSTEMATIC SCREENING FOR PHYTOCHEMICALS OF VARIOUS SOLVENT EXTRACTS OFTHEVETIA PERUVIANA SCHUM. LEAVES AND FRUIT RIND
Thevetia peruviana (S)Â (yellow oleander) is a tropical evergreen shrub or small tree that is in the Apocynaceae family as and closely related to Nerium oleander, is mainly known for its cardiac glycosides, which was tra...
QUALITY OF LIFE OF CHRONIC KIDNEY DISEASE PATIENTS WITH ROUTINE HEMODIALYSIS IN GENERAL HOSPITALS IN SLEMAN YOGYAKARTA
Objective: To elicit quality of life (QOL) of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin, to compare the QOL of CKD patients with routine hemodialysis receiving different ery...